Announcement of audit results of pharmaceutical companies!

The financial inspections of 77 pharmaceutical companies that began in 2019 finally yielded results.

On April 12, the Ministry of Finance issued an announcement, imposing administrative penalties on 19 of them.

According to the investigation, some pharmaceutical companies have the following problems:

One is to use false invoices and bills to arbitrage funds for external use;

The second is fictitious business matters or using pharmaceutical promotion companies to obtain funds;

The third is other accounting problems such as the irregular setting of account books.

The above behavior violates Article 9 of the "Accounting Law of the People's Republic of China" and other provisions.

Among the many fined companies, Jiangsu Wanbang Pharmaceutical Marketing Co.

For other pharmaceutical companies, the Department of Finance (Bureau) responsible for the inspection shall impose administrative punishments on the spot.

Attached:

The Ministry of Finance imposed administrative penalties on 19 pharmaceutical companies

1.

The inspection found that the company’s sales staff used unrelated personnel’s air tickets and invoices for reimbursement and settling of funds in 2018, involving an amount of 915,100 yuan.

The Ministry of Finance imposed a fine of 30,000 yuan on Beijing Cheng Nuo Mei Di Technology Co.

2.

The inspection found that the company listed 149 million yuan for academic seminars or experience exchange conferences in the medical field in 2018.

The Ministry of Finance imposed a fine of 30,000 yuan on Sanofi (Beijing) Pharmaceutical Co.

3.

The inspection found that the company had the following problems: First, in 2018, it inflated staff salaries by 7.

The Ministry of Finance imposed a fine of 50,000 yuan on Changbaishan Pharmaceutical Co.

4.

The inspection found that the company had the following problems: First, in 2018, it inflated staff salaries by RMB 4.
833 million, inflated travel expenses by RMB 5.
9833 million by over-reporting the number of days of business trips of sales staff, and inflated labor services by over-reporting the workload of labor dispatch personnel.
The dispatch cost was 4,720,200 yuan.
The second is to include the Fujian business promotion expenses in 2018, and the invoice issued by Zhangshu Huisheng Information Consulting Co.
, Ltd.
is a false invoice, involving an amount of 1.
7 million yuan.
Third, in 2018, the clinical expenses of 23 medical institutions across the country were 13.
7 million yuan, which was accounted for by the medical institution outpatient fee receipts provided by the business promotion service provider.
After verification, the above-mentioned outpatient fee receipts are inconsistent with the outpatient fee receipt numbers and official seals actually used by medical institutions.

The Ministry of Finance imposed a fine of 50,000 yuan on Tonghua Yusheng Pharmaceutical Co.
, Ltd.
according to law.

5.
Jiangsu Wanbang Pharmaceutical Marketing Co.
, Ltd.

The inspection found that the company paid sales and promotion expenses for individual agents in 2018, and part of the invoice attached to the voucher was issued by a third-party company that has no substantial business dealings with the company, involving an amount of 140 million yuan.

The Ministry of Finance imposed a fine of 50,000 yuan on Jiangsu Wanbang Pharmaceutical Marketing Co.
, Ltd.
according to law.

6.
Jiangsu Hengrui Pharmaceutical Co.
, Ltd.

The inspection found that the company had the following problems: First, in 2018, non-company air tickets were used to reimburse expert lecture fees, review fees, and hosting fees, involving an amount of 1.
088 million yuan.
Second, in 2018, the company’s employee welfare incentive expenses were included in the invoices of air tickets, tolls, consulting fees, and advertising fees that were not incurred by the company, involving an amount of RMB 2,149,100.
Third, in 2018, the affiliated Lianyungang Comprehensive Second Office reimbursed sales staff subsidies, gifts for customers, meals for academic activities, etc.
, with an amount of 961,900 yuan incurred by the invoice of the bridge and toll fees that did not occur in the unit.

The Ministry of Finance imposed a fine of 50,000 yuan on Jiangsu Hengrui Pharmaceutical Co.
, Ltd.
according to law.

7.
Shanghai Xinyi United Medical and Medicinal Materials Co.
, Ltd.

The inspection found that the company had the following problems: First, its affiliated Xinyi Pharmaceutical Business Department inflated travel expenses of RMB 20,033,600 in 2018, which were listed as fueling invoices, but could not provide details of the recharge card number, expense approval form and other information.
Spot checks revealed that some of the invoices were fake invoices.
The second is that the subsidiary Xinyi United Business Department listed the research and consulting expenses in the business promotion fee in 2018, and the attached part of the information is not true.
After spot checks, there were problems such as plagiarism of the research report, the date of signing the consulting contract earlier than the date of establishment of the consulting company, and the inconsistency between the content of the research and the contract agreement, etc.
The amount involved was RMB 6,316,200.

The Ministry of Finance imposed a fine of 50,000 yuan on Shanghai Xinyi United Medical and Medicinal Materials Co.
, Ltd.
according to law.

8.
Shanghai Shangyao Xinya Pharmaceutical Co.
, Ltd.

The inspection found that the company has the following problems: First, the following information on the meeting fees listed in 2018 is false, there are similarities in photos of different promotion meetings, forged meeting locations and sign-in forms, and the records of meetings held at different locations at the same time are artificial The same person and other issues involved an amount of 8.
4039 million yuan.
The second is that the data attached to the market research expenses in 2018 is false.
There are problems with plagiarism in the research report and the same problem as the market analysis report in different regions, involving an amount of 13.
1832 million yuan.
The third is that the data attached to the travel expenses in 2018 is not true, there are no field registration, approval forms, transportation expenses, some meeting sign-in forms are blank, different meetings photos are the same or the sign-in forms are the same, etc.
, involving an amount of 12.
394 million yuan .

The Ministry of Finance imposed a fine of 50,000 yuan on Shanghai Shangyao Xinya Pharmaceutical Co.
, Ltd.
according to law.

9.
Shanghai Xinyi Tianyi Pharmaceutical Co.
, Ltd.

The inspection found that the company's 2018 academic activity fee attached part of the information is not true, some academic conferences have invitation letters without specific participants, transportation and accommodation arrangements, and detailed agenda information.
The listed conference address is invalid.
, The conference sign-in form has no real-name signature and other issues, involving an amount of RMB 5.
6572 million.

The Ministry of Finance imposed a fine of 50,000 yuan on Shanghai Xinyi Tianyi Pharmaceutical Co.
, Ltd.
according to law.

10.
Shandong Xinyi Pharmaceutical Co.
, Ltd.

The inspection found that the company listed part-time salesperson expenses and office lease expenses in 2018, and the certificates were attached with fueling invoices and transportation invoices, involving an amount of 11.
373 million yuan.

The Ministry of Finance imposed a fine of 50,000 yuan on Shandong Xinyi Pharmaceutical Co.
, Ltd.
according to law.

11.
Fujian Gutian Pharmaceutical Co.
, Ltd.

The inspection found that from 2017 to June 30, 2019, the company paid Fujian Yitong Tianxia Health Pioneer Park Co.
, Ltd.
31.
3410 million yuan in the name of business promotion fees, which after deducting taxes, passed the Dongjin Medical Information of Wushi, Xiuyu District, Putian City The consulting department and other 26 supplier accounts transferred 29,572,900 yuan of funds back to 3 personal bank accounts controlled by employees of Fujian Gutian Pharmaceutical Co.
, Ltd.

The Ministry of Finance imposed a fine of 50,000 yuan on Fujian Gutian Pharmaceutical Co.
, Ltd.
according to law.

12.
Shandong Buchang Pharmaceutical Co.
, Ltd.

The inspection found that the company paid funds to the pharmaceutical promotion company in the name of consulting fees and market promotion fees, which were then transferred to the company’s agents by the pharmaceutical promotion company, involving an amount of 51,223,900 yuan.

The Ministry of Finance imposed a fine of 50,000 yuan on Shandong Buchang Pharmaceutical Co.
, Ltd.
according to law.

13.
Merck Serono Co.
, Ltd.

The inspection found that the accounting subjects of the company were set up in accordance with the unified code of the overseas parent company, listed in English, and Chinese were not used.

The Ministry of Finance imposed a fine of 30,000 yuan on Merck Serono Ltd.
in accordance with the law.

14.
Jiangsu Haosen Pharmaceutical Group Co.
, Ltd.

The inspection found that the company has the following problems: First, in 2018, the consulting review fee and advertising fee were paid, and some invoices were attached.
After inquiring the State Administration of Taxation's national value-added tax invoice inspection platform, the result was "no such ticket found" or "inconsistent" ", the amount involved is 129 million yuan.
Second, in 2018, the consulting review fee of 27 information consulting service departments was listed as 16 million yuan.
The third is that the attached part of the data on the meeting fees listed in 2018 is false, involving an amount of 2,740,600 yuan.
Fourth, in 2018, the office supplies expenses were inflated by RMB 4,817,100.
The attached invoice showed that the purchased products were pens, notebooks, etc.
, but after investigation, they did not actually purchase them.

The Ministry of Finance imposed a fine of 50,000 yuan on Jiangsu Haosen Pharmaceutical Group Co.
, Ltd.
according to law.

15.
Eli Lilly (Shanghai) Management Co.
, Ltd.

The inspection found that the company used electronic computers for accounting and failed to set up general ledgers, subsidiary ledgers and other accounting books in accordance with the provisions of the national unified accounting system.

The Ministry of Finance imposed a fine of 30,000 yuan on Eli Lilly (Shanghai) Management Co.
, Ltd.
according to law.

16.
Guangdong Yili Pharmaceutical Co.
, Ltd.

The inspection found that the company had the following problems: First, in 2018, it paid 274,400 yuan and 720,000 yuan to the Creative Advertising Department of Huazhou City and Yangyang Commodity Information Consulting Service Department of Luoding City in the name of advertising fees and marketing fees.
After receiving the money, the person transfers it back to the personal accounts of the employees and their family members of Guangdong Yili Pharmaceutical Co.
, Ltd.
The second is to pay Guangzhou Zairan Enterprise Management Service Co.
, Ltd.
466,000 yuan in the name of consulting and research fees, but failed to provide research-related agreements, fund payment vouchers and other materials.

The Ministry of Finance imposed a fine of 30,000 yuan on Guangdong Yili Pharmaceutical Co.
, Ltd.
according to law.

17.
Yili Pharmaceutical (Luoding) Co.
, Ltd.

The inspection found that the company paid 360,000 yuan to the Yangyang Commodity Information Consultation Service Department of Luoding City in 2018 in the name of marketing fees.
After the latter received the payment, it transferred it to the employees of Yili Pharmaceutical (Luoding) Co.
, Ltd.
For the personal account of new drug promotion customers, the company cannot provide the agreement or supporting materials corresponding to the above-mentioned business.

The Ministry of Finance imposed a fine of 30,000 yuan on Yili Pharmaceutical (Luoding) Co.
, Ltd.
according to law.

18.
Shenzhen China Resources Sanjiu Pharmaceutical Trading Co.
, Ltd.

The inspection found that the company had the following problems: First, the production cost of the video shooting project listed in 2018 was false, involving an amount of 13.
237 million yuan.
The second is that the logistics supervision project fee listed in 2018 is false, involving an amount of 3.
2020 million yuan.
The third is that the company’s headquarters and the Guangdong area listed false conference fees in 2018, involving an amount of RMB 88,481,200.
Fourth, the company’s headquarters and Guangdong area reported false research fees in 2018, involving an amount of RMB 59,521,700.

The Ministry of Finance imposed a fine of 50,000 yuan on Shenzhen China Resources Sanjiu Pharmaceutical Trading Co.
, Ltd.
according to law.

19.
Yunnan Longhai Natural Plant Pharmaceutical Co.
, Ltd.

The inspection found that the company inflated sales expenses by RMB 1,244,400 by over-reporting the number of business promoters.

The Ministry of Finance imposed a fine of 30,000 yuan on Yunnan Longhai Natural Plant Pharmaceutical Co.
, Ltd.
according to law.